Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 68 out of 100. Prevention and risk

Topic: Risk, prevention and care in population studies

Plain-language summary

Vaccines to prevent herpes zoster have been associated with reduced dementia risk. We conducted a retrospective matched cohort study of Kaiser Permanente Southern California members aged ≥65 years who received two doses of RZV 4 weeks-6 months apart between 01 April 2018 and 31 December 2020, with no dementia diagnoses or dementia medications prior to or within 6 months of their second RZV dose. Cox regression with inverse probability of treatment weighting was used to estimate adjusted hazard ratios (aHRs). The study included 65,800 RZV-vaccinated individuals and 263,200 unvaccinated matches. Vaccination with two doses of RZV was associated with a 51% lower risk of dementia (aHR: 0.49 [95% confidence interval (CI): 0.46-0.51]); aHRs were comparable across age, and racial and ethnic groups, but the risk reduction was stronger in females compared to males. In an evaluation of potential healthy vaccinee bias, the aHR of dementia for RZV compared to Tdap was 0.73 (95% CI: 0.67-0.79). Vaccination with two doses of RZV is associated with a statistically significant reduction in the risk of dementia in adults aged ≥65 years. After accounting for healthy vaccinee bias, RZV vaccination remains associated with a statistically significant lower risk of dementia.

What this study adds

Evidence grade: Moderate

This is a follow-up (cohort) study of 65,800 participants. This retrospective cohort study found that two doses of recombinant zoster vaccine were associated with a 51% lower risk of dementia in adults aged 65 and older, and the association remained significant after accounting for healthy vaccinee bias. Reported effect size: aHR: 0.49.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Rayens, E. A., Sy, L. S., Qian, L., Ackerson, B. K., Tubert, J. E., Luo, Y., et al. (2026). Recombinant zoster vaccine is associated with a reduced risk of dementia. Nature Communications. https://doi.org/10.1038/s41467-026-69289-0

Vancouver

Rayens EA, Sy LS, Qian L, Ackerson BK, Tubert JE, Luo Y, et al. Recombinant zoster vaccine is associated with a reduced risk of dementia. Nature Communications. 2026. doi:10.1038/s41467-026-69289-0. PMID: 41663414.

BibTeX

@article{rayens2026-41663414,
  author  = {Rayens, Emily A. and Sy, Lina S. and Qian, Lei and Ackerson, Bradley K. and Tubert, Julia E. and Luo, Yi and Modha, Punam P. and Calderon, Raul and others},
  title   = {{Recombinant zoster vaccine is associated with a reduced risk of dementia}},
  journal = {Nature Communications},
  year    = {2026},
  doi     = {10.1038/s41467-026-69289-0},
  pmid    = {41663414},
  url     = {https://doi.org/10.1038/s41467-026-69289-0}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

Key findings

Why it matters

This retrospective cohort study found that two doses of recombinant zoster vaccine were associated with a 51% lower risk of dementia in adults aged 65 and older, and the association remained significant after accounting for healthy vaccinee bias. The study is observational, so it cannot prove that the vaccine causes the reduced risk.

Study details

How this study scored 68/100
How this study's score is builtJournal tier 9 of 10; Journal's citation record 4 of 4; Study design 7 of 12; Strength of evidence 3 of 5; Peer-review validation 10 of 10; How recent 5 of 5; Sample size 4 of 4; Effect reported 3 of 3; Studied in people 3 of 3; Randomized / blinded 0 of 2; Times cited 2 of 7; Citations per year 2 of 5; Impact for its field and year 6 of 6; Cited by studies here 0 of 6; Still being cited 1 of 4; Senior author's track record 2 of 4; Institution's track record 1 of 3; Multicenter collaboration 2 of 3; Indexed in PubMed 2 of 2; Free to read 2 of 2. Total 68 of 100.68 of 100 points earned32 not earned

Published in a leading specialty journal, and it is a cohort study following people over time. Scored zero for randomized / blinded because the record does not state it.

ComponentPointsWhy
Journal tier 9 / 10 Tier 2 — leading specialty journal (Nature Communications)
Journal's citation record 4 / 4 Nature Communications: journal h-index 747 (OpenAlex, 2026-10-29)
Study design 7 / 12 A cohort study following people over time
Strength of evidence 3 / 5 Rated “moderate” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 5 / 5 2026 — within 1 year(s) of the newest study here
Sample size 4 / 4 65,800 participants
Effect reported 3 / 3 Effect reported with a statistic (interval, p-value, ratio or similar)
Studied in people 3 / 3 Studied in people (participant count stated)
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 2 / 7 Cited 14 times (OpenAlex, 2026-10-10)
Citations per year 2 / 5 7.0 citations a year over 2 year(s) since 2026
Impact for its field and year 6 / 6 Cited 62.6× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 0 / 6 No other study in this library cites it
Still being cited 1 / 4 Cited 14 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 2 / 4 Last-listed author Hung Fu Tseng: h-index 45 (OpenAlex, whole career)
Institution's track record 1 / 3 University of Maryland, Baltimore: institution h-index 970 (OpenAlex)
Multicenter collaboration 2 / 3 OpenAlex lists 4 institution(s) in 1 country
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 41663414)
Free to read 2 / 2 Free to read
Total 68 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here.

Related studies in Prevention and risk from nearby years

Also tagged “biobank”

1,084 studies in the library carry the topic tag “biobank”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,084 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Prevention and risk

See all studies in Prevention and risk →